This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
The HERG screening market size has grown rapidly in recent years. It will grow from $1.62 billion in 2024 to $1.84 billion in 2025 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to increasing drug development activities, regulatory requirements, increasing awareness of cardiac safety, rising incidence of cardiac disorders.
The HERG screening market size is expected to see rapid growth in the next few years. It will grow to $2.9 billion in 2029 at a compound annual growth rate (CAGR) of 12%. The growth in the forecast period can be attributed to expansion of personalized medicine, increasing outsourcing of drug development activities, emerging markets and research, focus on non-cardiac safety assessments. Major trends in the forecast period include advanced in vitro models, integration of genomic and proteomic data, advancements in computational approaches, focus on pediatric drug safety, collaborations for data sharing and standardization.
The increasing number of patients with heart disorders is expected to drive the expansion of the HERG screening market in the coming years. Heart disorders, also referred to as cardiovascular diseases, encompass a range of conditions affecting the heart and blood vessels. These issues can impair the heart's functionality and may result in serious health complications. Factors contributing to these disorders include unhealthy lifestyles, aging populations, genetic predispositions, diabetes, and metabolic syndrome. HERG screening plays a critical role in identifying potential drug candidates, reducing the risk of adverse cardiac events like life-threatening arrhythmias, particularly torsade de pointes (TdP), and enhancing patient outcomes. For example, a report by the Centers for Disease Control and Prevention (CDC) in May 2023 revealed that 1 in 20 adults aged 20 and above in the United States have cardiovascular diseases, with 695,000 people affected and 375,476 deaths due to these conditions. Similarly, data from the Office for National Statistics in the UK, published in March 2022, indicated that 20,061 people died of heart attacks, an increase from the previous year. Thus, the growing prevalence of heart disorders is contributing to the expanding HERG screening market.
Key companies in the HERG screening market are actively focusing on innovative solutions, including GLP-certified HERG screening services, to enhance cardiac safety assessments during drug development processes. GLP-certified HERG screening involves screening the human ether-à-go-go related gene (hERG) using the conventional whole-cell patch-clamp technique, ensuring compliance with regulatory guidelines such as ICH S7A and ICH S7B. These guidelines are critical for safety pharmacology studies in drug development. For example, in August 2023, Metrion Biosciences Ltd., a UK-based pharmaceutical company, introduced the GLP-certified hERG screening service. This service is designed to support small-molecule therapeutic development, complement the existing cardiac safety service portfolio, and employ the conventional whole-cell patch-clamp technique to assess potential cardiac liabilities before entering Phase 1 clinical trials. It provides regulatory guidance for safety pharmacology studies and offers high-quality biology services for ion channel targets.
In January 2022, the Tox21 research program was established through a partnership among several US-based agencies, including the National Toxicology Program, the Environmental Protection Agency, the National Center for Advancing Translational Science, and the Food and Drug Administration. This collaboration aims to enhance the methods used for chemical toxicity testing. The agencies work together to rapidly and efficiently assess the safety of various chemicals, including those found in everyday products. Specifically for HERG screening, their objective is to analyze the molecular mechanisms of these chemicals, prioritize those requiring further investigation, and develop predictive models to evaluate their effects on living organisms.
Major companies operating in the HERG screening market are Eurofins-Cerep SA., Aviva Biosciences Inc., AstraZeneca Public Limited Company, Merck KGaA, Charles River Laboratories Inc., Abcam Public Limited Company, Molecular Devices LLC, Caliper Life Sciences Inc., Crprotex Limited, ChanTest Corporation, Creative bioarray Inc., Cellular Dynamics International Inc., Nanion Technologies, Essen Bioscience, ABR-Affinity BioReagents Inc., ACEA Biosciences Inc., Metrion biosciences Inc., Aurora Biomed Inc., Aureus Sciences, RedShift BioAnalytics, B'SYS GmbH, Cambridge Bioscience Ltd., Sophion Bioscience Inc., Fluxion Biosciences Inc., ChemAxon Ltd.
North America was the largest region in the HERG screening market in 2024. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the herg screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the herg screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The HERG screening market includes revenues earned by entities by providing services such as in vitro HERG assays, patch clamp electrophysiology, data analysis and interpretation, consultation and regulatory support, and customized assay development. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
Human Ether-à-go-go-related gene (HERG) screening is a crucial step in evaluating the potential cardiotoxic effects of a drug or compound. This screening process plays a vital role in preclinical safety assessment within the drug discovery and development phases, serving to guarantee the safety and effectiveness of newly developed therapeutic agents.
HERG screening encompasses two primary categories, gene KCNH2 and mutant KCNH2. The KCNH2 gene, also recognized as the human ether-à-go-go-related gene (hERG) or hERG gene, encodes the alpha subunit of a potassium ion channel pivotal in the regulation of the heart's electrical activity. This gene encompasses diverse ion channels, including both voltage-gated and ligand-gated variations. Its applications span across various therapeutic domains, including antiarrhythmics, antipsychotics, antibiotics, and others, underscoring its critical role in multiple medical contexts.
The HERG screening market research report is one of a series of new reports that provides HERG screening market statistics, including HERG screening industry global market size, regional shares, competitors with a HERG screening market share, detailed HERG screening market segments, market trends and opportunities, and any further data you may need to thrive in the HERG screening industry. This HERG screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The HERG screening market size has grown rapidly in recent years. It will grow from $1.62 billion in 2024 to $1.84 billion in 2025 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to increasing drug development activities, regulatory requirements, increasing awareness of cardiac safety, rising incidence of cardiac disorders.
The HERG screening market size is expected to see rapid growth in the next few years. It will grow to $2.9 billion in 2029 at a compound annual growth rate (CAGR) of 12%. The growth in the forecast period can be attributed to expansion of personalized medicine, increasing outsourcing of drug development activities, emerging markets and research, focus on non-cardiac safety assessments. Major trends in the forecast period include advanced in vitro models, integration of genomic and proteomic data, advancements in computational approaches, focus on pediatric drug safety, collaborations for data sharing and standardization.
The increasing number of patients with heart disorders is expected to drive the expansion of the HERG screening market in the coming years. Heart disorders, also referred to as cardiovascular diseases, encompass a range of conditions affecting the heart and blood vessels. These issues can impair the heart's functionality and may result in serious health complications. Factors contributing to these disorders include unhealthy lifestyles, aging populations, genetic predispositions, diabetes, and metabolic syndrome. HERG screening plays a critical role in identifying potential drug candidates, reducing the risk of adverse cardiac events like life-threatening arrhythmias, particularly torsade de pointes (TdP), and enhancing patient outcomes. For example, a report by the Centers for Disease Control and Prevention (CDC) in May 2023 revealed that 1 in 20 adults aged 20 and above in the United States have cardiovascular diseases, with 695,000 people affected and 375,476 deaths due to these conditions. Similarly, data from the Office for National Statistics in the UK, published in March 2022, indicated that 20,061 people died of heart attacks, an increase from the previous year. Thus, the growing prevalence of heart disorders is contributing to the expanding HERG screening market.
Key companies in the HERG screening market are actively focusing on innovative solutions, including GLP-certified HERG screening services, to enhance cardiac safety assessments during drug development processes. GLP-certified HERG screening involves screening the human ether-à-go-go related gene (hERG) using the conventional whole-cell patch-clamp technique, ensuring compliance with regulatory guidelines such as ICH S7A and ICH S7B. These guidelines are critical for safety pharmacology studies in drug development. For example, in August 2023, Metrion Biosciences Ltd., a UK-based pharmaceutical company, introduced the GLP-certified hERG screening service. This service is designed to support small-molecule therapeutic development, complement the existing cardiac safety service portfolio, and employ the conventional whole-cell patch-clamp technique to assess potential cardiac liabilities before entering Phase 1 clinical trials. It provides regulatory guidance for safety pharmacology studies and offers high-quality biology services for ion channel targets.
In January 2022, the Tox21 research program was established through a partnership among several US-based agencies, including the National Toxicology Program, the Environmental Protection Agency, the National Center for Advancing Translational Science, and the Food and Drug Administration. This collaboration aims to enhance the methods used for chemical toxicity testing. The agencies work together to rapidly and efficiently assess the safety of various chemicals, including those found in everyday products. Specifically for HERG screening, their objective is to analyze the molecular mechanisms of these chemicals, prioritize those requiring further investigation, and develop predictive models to evaluate their effects on living organisms.
Major companies operating in the HERG screening market are Eurofins-Cerep SA., Aviva Biosciences Inc., AstraZeneca Public Limited Company, Merck KGaA, Charles River Laboratories Inc., Abcam Public Limited Company, Molecular Devices LLC, Caliper Life Sciences Inc., Crprotex Limited, ChanTest Corporation, Creative bioarray Inc., Cellular Dynamics International Inc., Nanion Technologies, Essen Bioscience, ABR-Affinity BioReagents Inc., ACEA Biosciences Inc., Metrion biosciences Inc., Aurora Biomed Inc., Aureus Sciences, RedShift BioAnalytics, B'SYS GmbH, Cambridge Bioscience Ltd., Sophion Bioscience Inc., Fluxion Biosciences Inc., ChemAxon Ltd.
North America was the largest region in the HERG screening market in 2024. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the herg screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the herg screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The HERG screening market includes revenues earned by entities by providing services such as in vitro HERG assays, patch clamp electrophysiology, data analysis and interpretation, consultation and regulatory support, and customized assay development. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
Human Ether-à-go-go-related gene (HERG) screening is a crucial step in evaluating the potential cardiotoxic effects of a drug or compound. This screening process plays a vital role in preclinical safety assessment within the drug discovery and development phases, serving to guarantee the safety and effectiveness of newly developed therapeutic agents.
HERG screening encompasses two primary categories, gene KCNH2 and mutant KCNH2. The KCNH2 gene, also recognized as the human ether-à-go-go-related gene (hERG) or hERG gene, encodes the alpha subunit of a potassium ion channel pivotal in the regulation of the heart's electrical activity. This gene encompasses diverse ion channels, including both voltage-gated and ligand-gated variations. Its applications span across various therapeutic domains, including antiarrhythmics, antipsychotics, antibiotics, and others, underscoring its critical role in multiple medical contexts.
The HERG screening market research report is one of a series of new reports that provides HERG screening market statistics, including HERG screening industry global market size, regional shares, competitors with a HERG screening market share, detailed HERG screening market segments, market trends and opportunities, and any further data you may need to thrive in the HERG screening industry. This HERG screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. HERG Screening Market Characteristics3. HERG Screening Market Trends and Strategies4. HERG Screening Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, Covid and Recovery on the Market32. Global HERG Screening Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the HERG Screening Market34. Recent Developments in the HERG Screening Market
5. Global HERG Screening Growth Analysis and Strategic Analysis Framework
6. HERG Screening Market Segmentation
7. HERG Screening Market Regional and Country Analysis
8. Asia-Pacific HERG Screening Market
9. China HERG Screening Market
10. India HERG Screening Market
11. Japan HERG Screening Market
12. Australia HERG Screening Market
13. Indonesia HERG Screening Market
14. South Korea HERG Screening Market
15. Western Europe HERG Screening Market
16. UK HERG Screening Market
17. Germany HERG Screening Market
18. France HERG Screening Market
19. Italy HERG Screening Market
20. Spain HERG Screening Market
21. Eastern Europe HERG Screening Market
22. Russia HERG Screening Market
23. North America HERG Screening Market
24. USA HERG Screening Market
25. Canada HERG Screening Market
26. South America HERG Screening Market
27. Brazil HERG Screening Market
28. Middle East HERG Screening Market
29. Africa HERG Screening Market
30. HERG Screening Market Competitive Landscape and Company Profiles
31. HERG Screening Market Other Major and Innovative Companies
35. HERG Screening Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
HERG Screening Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on herg screening market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for herg screening? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The herg screening market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: Gene KCNH2; Mutant KCNH22) By Ion Channel: Voltage-Gated; Ligand Gated
3) By Applications: Antiarrhythmic; Antipsychotic; Antibiotics; Other Applications
Subsegmeents:
1) By Gene KCNH2: Wild-Type KCNH2; Recombinant KCNH22) By Mutant KCNH2: Mutations: Missense Mutations; Nonsense Mutations; Frameshift Mutations
Key Companies Mentioned: Eurofins-Cerep SA.; Aviva Biosciences Inc.; AstraZeneca Public Limited Company; Merck KGaA; Charles River Laboratories Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this HERG Screening market report include:- Eurofins-Cerep SA.
- Aviva Biosciences Inc.
- AstraZeneca Public Limited Company
- Merck KGaA
- Charles River Laboratories Inc.
- Abcam Public Limited Company
- Molecular Devices LLC
- Caliper Life Sciences Inc.
- Crprotex Limited
- ChanTest Corporation
- Creative bioarray Inc.
- Cellular Dynamics International Inc.
- Nanion Technologies
- Essen Bioscience
- ABR-Affinity BioReagents Inc.
- ACEA Biosciences Inc.
- Metrion biosciences Inc.
- Aurora Biomed Inc.
- Aureus Sciences
- RedShift BioAnalytics
- B'SYS GmbH
- Cambridge Bioscience Ltd.
- Sophion Bioscience Inc.
- Fluxion Biosciences Inc.
- ChemAxon Ltd.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 200 |
Published | March 2025 |
Forecast Period | 2025 - 2029 |
Estimated Market Value ( USD | $ 1.84 Billion |
Forecasted Market Value ( USD | $ 2.9 Billion |
Compound Annual Growth Rate | 12.0% |
Regions Covered | Global |
No. of Companies Mentioned | 26 |